A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

Trial Profile

A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Terbinafine (Primary)
  • Indications Onychomycosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Moberg Pharma
  • Most Recent Events

    • 08 Aug 2017 According to a Moberg Pharma media release, enrolment for two phase 3 studies of MOB-015 has taken longer than expected and the company have taken a number of measures to speed up the process and are now on the right track, however enrolment will likely not be completed this year with somewhat higher costs as a result.
    • 30 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 28 Sep 2016 According to Moberg Pharma media release, this study is designed to support registration in North America, Europe and other major markets.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top